HPP Japan

Development of a Research Platform Through Human Phenotype Data Collection and Elucidation of Factors Associated with Disease Onset and Progression

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030260192

Enrollment

2000

Registered

2026-06-05

Start date

2026-06-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer and hematologic malignancies (excluding non-melanoma skin cancer), acute hematologic disorder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Men and women aged 40-69 at pre-screening 2) Individuals who are capable of visiting the CTC at baseline and have a will to continue to visit the CTC throughout the follow-up period at pre-screening 3) Individuals who are able and willing to sign a consent form at the time of the baseline visit to the CTC 4) Own a smartphone capable of downloading the app for this project and have the ability to use it

Exclusion criteria

Exclusion criteria: 1)Individuals who are pregnant or within 2 months after pregnancy 2)Individuals who are on infertility treatment or within 2 months after the last infertility treatment (women only) 3)Individuals who have malignancy, recurrent or metastatic, that is either untreated or undergoing treatment, or a certain period of time has not passed since the last treatment at pre-screening (for chemotherapy, less than 1 year from the date of the last administration; for radiotherapy, less than 2 months from the day of the last exposure) 4)Individuals who have a history of chronic or acute hepatitis 5)Individuals who have a history of HIV infection, hepatitis B or C virus infection 6)Individuals who have diagnosed with liver cirrhosis 7)Individuals who are under dialysis treatment 8)Individuals who have poorly controlled disease or symptoms (with unstable symptoms and clinical laboratory test results despite treatments) 9)Individuals who are not capable of continued participation in this study due to impaired cognitive, intellectual, or mental function

Design outcomes

Primary

Measure	Time frame
Identification of phenotypes associated with disease onset and progression, survival, healthy life expectancy, age-related changes, and major health events	—

Contacts

Public ContactHirayama Yumiko

Pheno.AI Japan Ltd.

yumiko@pheno.ai+81-3-5403-3560

Outcome results